BCL2A1 and fibrosarcoma: Several published papers have found that NF-κB binds to the promoters of BCL2, BCL2A1, and MCL1 and activates their expression in many cell types, such as prostate cancer cells [15], esophageal squamous carcinoma cells [16], and fibrosarcoma cells [17].